Quarterly report pursuant to Section 13 or 15(d)

GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)

v3.22.2.2
GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)
 6 Months Ended
Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
SCHEDULE OF IDENTIFIABLE INTANGIBLE ASSETS CARRYING VALUE

  

    (Years)     Amount     Amount  
          As of June 30, 2022     As of December 31, 2021  
    Life     Carrying     Carrying  
    (Years)     Amount     Amount  
          (unaudited)        
Asuragen acquisition:                        
Thyroid     9     $ 8,519     $ 8,519  
RedPath acquisition:                        
Pancreas test     7       16,141       16,141  
Barrett’s test     9       6,682       6,682  
BioPharma acquisition:                        
Trademarks     10       1,600       1,600  
Customer relationships     8       5,700       5,700  
                         
CLIA Lab     2.3       609       609  
                         
Total           $ 39,251     $ 39,251  
                         
Accumulated Amortization             (33,036 )     (31,964 )
                         
Net Carrying Value           $ 6,215     $ 7,287  
SCHEDULE OF FUTURE ESTIMATED AMORTIZATION EXPENSE

 

2022     2023     2024     2025     2026  
                                     
$ 1,071     $ 1,734     $ 873     $ 873     $ 873  
SCHEDULE OF GOODWILL CARRYING VALUE

The following table displays a roll forward of the carrying amount of goodwill from December 31, 2021 to June 30, 2022:

 

    Carrying  
    Amount  
Balance as of December 31, 2021   $ 8,433  
Adjustments     -  
Balance as of June 30, 2022   $ 8,433